Newest studies

Dissecting Alzheimer Disease Heritability Across Multiple Populations

45/100 ✓ Peer-reviewed Genetics Alzheimer s & Dementia

Key finding: Regardless of method or adjustment, the resulting heritability estimates were highly variable across populations. +4 more findings

• Genetics

Full summary, score breakdown and related studies → Original source

Novel sex‐specific candidate loci associated with Alzheimer disease identified through sex‐aware multi‐ancestry genome‐wide meta‐analysis

57/100 ✓ Peer-reviewed Genetics Alzheimer s & Dementia

Key finding: Cross-ancestry sex-stratified analyses identified several loci with evidence of interaction (p 0.05). +4 more findings

• Genetics

Full summary, score breakdown and related studies → Original source

Hormone replacement therapy in women and vascular risk factors modify the association of a multi‐ancestry polygenic risk score with Alzheimer disease and related traits

38/100 ✓ Peer-reviewed Genetics Alzheimer s & Dementia

Key finding: The AD PRS was associated with AD in the ADSP sample, with odds ratios per standard deviation ranging from 1.14 to 1.52 across ancestry groups and robust validation in independent cohorts (Figure 1). +4 more findings

• Genetics
• Risk Factors

Full summary, score breakdown and related studies → Original source

Genome‐Wide Analysis of Memory, Language, and Executive Function Reveals Domain‐Specific Genetic Architecture in Alzheimer Disease

30/100 ✓ Peer-reviewed Genetics Alzheimer s & Dementia

Key finding: We evaluated known AD-associated loci (Bellenguez et al. 2022) and 27 loci reached nominal significance (p < 0.05) in at least one cognitive domain. +4 more findings

• Genetics

Full summary, score breakdown and related studies → Original source

Alzheimer-Krankheit: Wert prädiktiver Blut-Biomarker untersucht

25/100 ✓ Peer-reviewed Biomarkers Fortschritte der Neurologie · Psychiatrie

Key finding: Als blutbasierter Biomarker zur Diagnose der Alzheimer-Krankheit gilt p-Tau217. +4 more findings

• Biomarkers

Full summary, score breakdown and related studies → Original source

Sensorimotor measures predict longitudinal cognitive decline and correlate with CSF and plasma biomarkers

40/100 ✓ Peer-reviewed Biomarkers Innovation in Aging

Key finding: Identifying early markers of cognitive decline in cognitively normal older adults is critical for dementia prevention. +1 more finding

• Biomarkers

Full summary, score breakdown and related studies → Original source

Sensorimotor measures predict longitudinal cognitive decline and correlate with CSF and plasma biomarkers

40/100 ✓ Peer-reviewed Biomarkers Innovation in Aging

Key finding: Identifying early markers of cognitive decline in cognitively normal older adults is critical for dementia prevention. +1 more finding

• Biomarkers

Full summary, score breakdown and related studies → Original source

Differing network patterns of functional connectivity and amyloid PET between tau PET subtypes

40/100 ✓ Peer-reviewed Biomarkers Alzheimer s & Dementia

Key finding: We replicated three distinct spatiotemporal subtypes of tau PET accumulation and their associations with individual differences and AD severity in an independent sporadic AD cohort. +2 more findings

• Brain Scans

Full summary, score breakdown and related studies → Original source

Plasma Biomarker Characterization of Alzheimer’s Disease Psychosis in Study ACP‐204‐006

33/100 ✓ Peer-reviewed Biomarkers Alzheimer s & Dementia

Key finding: In Part 1 (currently ongoing), between February 6, 2024, and December 27, 2024, 322 adults were screened, of whom 75 (aged 59-89 years) met NIA-AA and IPA criteria. +4 more findings

• Biomarkers
• Clinical Trials

Full summary, score breakdown and related studies → Original source

Differing network patterns of functional connectivity and amyloid PET between tau PET subtypes

40/100 ✓ Peer-reviewed Biomarkers Alzheimer s & Dementia

Key finding: We replicated three distinct spatiotemporal subtypes of tau PET accumulation and their associations with individual differences and AD severity in an independent sporadic AD cohort. +2 more findings

• Brain Scans

Full summary, score breakdown and related studies → Original source

Dream recall in cognitively healthy older adults: associations with blood p ‐tau217 levels, APOE ε4 carriage, and cognitive decline

44/100 ✓ Peer-reviewed Biomarkers Alzheimer s & Dementia

Key finding: Dream recall status was associated with blood p ‐tau217 levels, APOE ε4 carriage, and future cognitive decline among older individuals cognitively healthy at baseline. +4 more findings

• Genetics

Full summary, score breakdown and related studies → Original source

Adaptation of a Protocol for Disclosure of Amyloid PET Results for Adults with Down Syndrome and Their Caregivers

40/100 ✓ Peer-reviewed Biomarkers Alzheimer s & Dementia

Key finding: Adults with DS are often supported by family caregiver(s), who face challenges including lack of awareness of the increased risk of developing AD, difficulty in obtaining a timely diagnosis, limited resources for psychosocial support, and lack of access to clinical trials. +4 more findings

• Caregiving
• Brain Scans
• Down Syndrome

Full summary, score breakdown and related studies → Original source

Determining eligibility for anti‐amyloid treatments using blood biomarkers

39/100 ✓ Peer-reviewed Biomarkers Alzheimer s & Dementia

Key finding: A total of 143 patients with cognitive concerns were included who underwent a PrecivityAD2 test as part of their clinical evaluation. +4 more findings

• Biomarkers
• Treatments

Full summary, score breakdown and related studies → Original source

ApoE Genotyping and 12‐Month Longitudinal Tracking of p ‐Tau217 Using Fingerstick Collection in a Population‐Based Cohort

48/100 ✓ Peer-reviewed Biomarkers Alzheimer s & Dementia

Key finding: Our findings demonstrate the capability of a fingerstick collection to accurately quantify p ‐tau217 levels longitudinally and genotype ApoE. +4 more findings

• Genetics

Full summary, score breakdown and related studies → Original source

Development of a novel in‐house blood biomarker panel for early diagnosis of Alzheimer’s disease

39/100 ✓ Peer-reviewed Biomarkers Alzheimer s & Dementia

Key finding: We have successfully generated specific high affinity monoclonal antibodies against p -Tau217, p -Tau205, and N-terminus GFAP and have confirmed that these antibodies have the necessary specificity and sensitivity for the Simoa platform. +1 more finding

• Biomarkers

Full summary, score breakdown and related studies → Original source

Integrating MRI Volume and Plasma p ‐Tau217 for Amyloid Risk Stratification in Early Stage Alzheimer’s Disease

48/100 ✓ Peer-reviewed Biomarkers Alzheimer s & Dementia

Key finding: The study included 807 participants form K-ROAD (median age: 72.0 years, 58.7% female) and 230 from ADNI (median age: 70.9 years, 49.1% female). +4 more findings

• Brain Scans
• Early Stage

Full summary, score breakdown and related studies → Original source

Prediction of continuous amyloid positron emission tomography with fluid measures of phosphorylated tau and β-amyloid

46/100 ✓ Peer-reviewed Biomarkers EMBO Molecular Medicine

Key finding: CSF Aβ42/Aβ40 contributed most to identify Aβ-positivity, while continuous Aβ-PET load within the positive range was best predicted by plasma P-tau217.

• Biomarkers
• Brain Scans

Full summary, score breakdown and related studies → Original source

The economic value of plasma p ‐tau217 testing for patients presenting with cognitive impairment in the United States

33/100 ✓ Peer-reviewed Biomarkers Alzheimer s & Dementia

Key finding: In the study scenario, adding plasma p -tau217 testing to SCE reduced diagnostic costs by $342/patient, through more efficient use of amyloid PET and CSF testing. +4 more findings

• Biomarkers
• Policy

Full summary, score breakdown and related studies → Original source

Plasma Biomarker Association with Cognition in Uganda

49/100 ✓ Peer-reviewed Biomarkers Alzheimer s & Dementia

Key finding: Raw scores were converted to regression‐based Z‐scores and averaged at the domain and overall level. +4 more findings

• Biomarkers

Full summary, score breakdown and related studies → Original source

Clinical validation of a plasma p ‐tau217 immunoassay and evaluation of the impact of kidney function

33/100 ✓ Peer-reviewed Biomarkers Alzheimer s & Dementia

Key finding: The area under the receiver operating characteristic curve of plasma p -tau217 was 0.941. +4 more findings

Full summary, score breakdown and related studies → Original source

Analytical validation of plasma p ‐tau217 on the SP‐X platform

40/100 ✓ Peer-reviewed Biomarkers Alzheimer s & Dementia

Key finding: of 0.928 and bias of 6.0% (n =396, Deming regression, Figure 1). +4 more findings

Full summary, score breakdown and related studies → Original source

Modulatory effect of glial fibrillary acidic protein (GFAP) levels on the association between plasma p ‐tau217 levels and cognitive decline in older adults

46/100 ✓ Peer-reviewed Biomarkers Alzheimer s & Dementia

Key finding: Additionally, growing evidence suggests that neuroinflammation may modulate the effects of tau spread on cognitive impairment in AD [Peretti, Débora E., et al., Brain 147.12 (2024): 4094‐4104.]. +4 more findings

• Biomarkers

Full summary, score breakdown and related studies → Original source

Interplay between Alzheimer and vascular pathology as determinants of plasma neurofilament light in a memory clinic population

39/100 ✓ Peer-reviewed Biomarkers Alzheimer s & Dementia

Key finding: Vascular burden influences NfL levels, particularly in amyloid‐negative individuals. +4 more findings

• Biomarkers
• Early Stage
• Care Services

Full summary, score breakdown and related studies → Original source

Predicting onset of Alzheimer disease symptoms with a plasma %p‐tau217 clock

52/100 ✓ Peer-reviewed Biomarkers Alzheimer s & Dementia

Key finding: Two independently constructed %p‐tau217 plasma clocks had strong correlations with actual time measures and were consistent across the two cohorts. +2 more findings

• Biomarkers

Full summary, score breakdown and related studies → Original source

Alzheimer disease blood biomarkers and cognition in midlife

42/100 ✓ Peer-reviewed Biomarkers Alzheimer s & Dementia

Key finding: Older age, White race, APOE ε4 carrier, and diabetes were associated with biomarker levels indicative of higher AD risk (lower Aβ42/40; higher p-tau217, p-tau217/Aβ42, NfL, and GFAP). +4 more findings

• Biomarkers
• Risk Factors

Full summary, score breakdown and related studies → Original source